PRA Health Sciences,Inc. (NASDAQ:PRAH) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions.
On February27, 2019, PRA Health Sciences,Inc. (the “Company”) issued a press release announcing the results of the Company’s operations for the quarter and year ended December31, 2018. The press release is furnished as Exhibit 99.1 to this Report and is hereby incorporated by reference in this Item 2.02.
As provided in General Instruction B.2 of Form8-K, the information and exhibit contained in this Form8-K shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit |
Description of Document |
|
Press Release dated February 27, 2019
|
PRA Health Sciences, Inc. Exhibit
EX-99.1 2 q42018ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 FOR IMMEDIATE RELEASE PRA Health Sciences,…
To view the full exhibit click here
About PRA Health Sciences,Inc. (NASDAQ:PRAH)
PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Company’s service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.
